Antiplatelet Therapy for AIS Patients With Thrombocytopenia (PERSIST)
Acute Ischemic Stroke, Thrombocytopenia
About this trial
This is an interventional prevention trial for Acute Ischemic Stroke
Eligibility Criteria
Inclusion Criteria: Age > 18 years old Acute ischemic stroke or transient ischemic attack with onset < 7 days The last blood routine test before enrollment indicates platelet count < 100 x 10^9 and > 30 x 10^9 Exclusion Criteria: Chronic renal dysfunction (GFR < 30ml/min) or severe hepatic injury Indications for anticoagulation therapy, e.g. atrial fibrillation Myocardial infarction within 6 months before enrollment or received percutaneous coronary intervention in the past Have or plan to receive CEA or CAS in the following 3 months Life expectancy less than 1 year Plan to receive invasive surgery in the following 3 months and have high risk of uncontrollable bleeding Pregnant or lactating women Individuals identified by researchers as unsuitable for participation in the study due to other reasons.
Sites / Locations
- Second Affiliated Hospital, School of Medicine, Zhejiang UniversityRecruiting
Arms of the Study
Arm 1
Experimental
Intervention
Participants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole.